Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy

Breast Cancer Research and Treatment

Volumn 129, Issue 1, 2011, Pages 157-164

  Fakkert, Ingrid E ^a   Jansen, Liesbeth ^a   Meijer, Kees ^a   Kok, Theo ^a   Oosterwijk, Jan C ^a   Mourits, Marian J E ^a   De Bock, Geertruida H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

BRCA1; BRCA2; Breast cancer screening; MRI; pBSO; RRSO

Indexed keywords

ADULT; ARTICLE; BRCA2 GENE; BREAST CANCER; CANCER SCREENING; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK REDUCING SALPINGOOOPHORECTOMY; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MUTATION; OVARIECTOMY; RISK; SALPINGECTOMY; SENSITIVITY AND SPECIFICITY;

EID: 79960847998     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1423-4     Document Type: Article

References (28)

1. Nederlandse kankerregistratie (2008) Borstkankerincidentie in vrouwen per 100 000. IKCnet. http://www.ikcnet.nl/. Accessed 17 February 2011
2. EB Claus N Risch WD Thompson 1994 Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction Cancer 73 643 651 8299086 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5 1:STN:280:DyaK2c7jtVagug%3D%3D (Pubitemid 24046606)
3. A Antoniou PD Pharoah S Narod HA Risch JE Eyfjord JL Hopper N Loman, et al. 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 1117 1130 12677558 10.1086/375033 1:CAS:528:DC%2BD3sXjslagtbg%3D (Pubitemid 36530000)
4. S Chen G Parmigiani 2007 Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 1329 1333 17416853 10.1200/JCO.2006.09.1066 (Pubitemid 46706879)
5. DM Van Der Kolk GH De Bock BK Leegte M Schaapveld MJ Mourits J De Vries AH Van Der Hout JC Oosterwijk 2010 Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Breast Cancer Res Treat 124 643 651 20204502 10.1007/s10549-010-0805-3 1:CAS:528:DC%2BC3cXhtlyrsrjO
6. TR Rebbeck T Friebel HT Lynch SL Neuhausen L van 't Veer JE Garber GR Evans, et al. 2004 Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group J Clin Oncol 22 1055 1062 14981104 10.1200/JCO.2004.04.188 (Pubitemid 41095038)
7. BA Heemskerk-Gerritsen CT Brekelmans MB Menke-Pluymers AN van Geel MM Tilanus-Linthorst CC Bartels M Tan, et al. 2007 Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic Ann Surg Oncol 14 3335 3344 17541692 10.1245/s10434-007-9449-x (Pubitemid 350160099)
8. M Kriege CT Brekelmans C Boetes PE Besnard HM Zonderland IM Obdeijn RA Manoliu, et al. 2004 Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition N Engl J Med 351 427 437 15282350 10.1056/NEJMoa031759 1:CAS:528:DC%2BD2cXmtFalu7o%3D (Pubitemid 38988592)
9. E Warner DB Plewes KA Hill PA Causer JT Zubovits RA Jong MR Cutrara, et al. 2004 Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination JAMA 292 1317 1325 15367553 10.1001/jama.292.11.1317 1:CAS:528:DC%2BD2cXns12rs78%3D (Pubitemid 39223222)
10. MO Leach CR Boggis AK Dixon DF Easton RA Eeles DG Evans FJ Gilbert, et al. 2005 Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) Lancet 365 1769 1778 15910949 10.1016/S0140-6736(05)66646- 9 1:STN:280:DC%2BD2M3mvFCqtg%3D%3D (Pubitemid 40744657)
11. CK Kuhl S Schrading CC Leutner N Morakkabati-Spitz E Wardelmann R Fimmers W Kuhn, et al. 2005 Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer J Clin Oncol 23 8469 8476 16293877 10.1200/JCO.2004.00.4960
12. AJ Rijnsburger I Obdeyn R Kaas MMA Tilanus-Linthors C Boetes CE Loo, et al. 2010 BRCA1-Associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC study J Clin Oncol 28 5265 5273 21079137 10.1200/JCO.2009.27.2294 1:CAS:528:DC%2BC3MXhtVKqs7c%3D
13. NM Van de Velde MJ Mourits VJ de HJ Arts BK Leegte G Dijkhuis JC Oosterwijk, et al. 2009 Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 124 919 923 19035463 10.1002/ijc.24038
14. BB Hermsen RI Olivier RH Verheijen M van Beurden JA de Hullu LF Massuger CW Burger CT Brekelmans MJ Mourits GH de Bock KN Gaarenstroom HH van Boven TM Mooij MA Rookus 2007 No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study Br J Cancer 96 1335 1342 17426707 1:STN:280:DC%2BD2s3mt1yrsQ%3D%3D (Pubitemid 46685786)
15. H Meijers-Heijboer CT Brekelmans M Menke-Pluymers C Seynaeve A Baalbergen C Burger E Crepin, et al. 2003 Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation J Clin Oncol 21 1675 1681 12721241 10.1200/JCO.2003.09.052 (Pubitemid 46638577)
16. KA Metcalfe D Birenbaum-Carmeli J Lubinski J Gronwald H Lynch P Moller P Ghadirian, et al. 2008 International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers Int J Cancer 122 2017 2022 18196574 10.1002/ijc.23340 1:CAS:528:DC%2BD1cXkt1ChsL8%3D (Pubitemid 351441190)
17. TR Rebbeck ND Kauff SM Domchek 2009 Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 80 87 19141781 10.1093/jnci/djn442 1:CAS:528:DC%2BD1MXhtVehsbo%3D
18. Kwaliteitsinstituut voor de Gezondheidszorg CBO (2008) Richtlijn mammacarcinoom 2008. CBO. http://www.cbo.nl/Downloads/328/rl-mamma-08.pdf. Accessed 17 February 2011
19. National Institute of Clinical Excellence (NICE) (2006) National Institute of Clinical Excellence (NICE) guideline CG41 Familial Breast Cancer 2004 updated in 2006. NICE. http://www.nice.org.uk/CG41. Accessed 17 February 2011
20. MJ Kenkhuis GH de Bock PO Elferink HJ Arts JC Oosterwijk L Jansen MJ Mourits 2010 Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers Maturitas 66 310 314 20409655 10.1016/j.maturitas.2010.03.018 1:STN:280:DC%2BC3crns1amtA%3D%3D
21. AA Tardivon A Athanasiou F Thibault C El Khoury 2007 Breast imaging and reporting data system (BIRADS): magnetic resonance imaging Eur J Radiol 61 212 215 17145155 10.1016/j.ejrad.2006.08.036 (Pubitemid 46096699)
22. L Liberman JH Menell 2002 Breast imaging reporting and data system (BI-RADS) Radiol Clin N Am 40 409 430 12117184 10.1016/S0033-8389(01)00017-3 (Pubitemid 34765031)
23. S Obenauer KP Hermann E Grabbe 2005 Applications and literature review of the BI-RADS classification Eur Radiol 15 1027 1036 15856253 10.1007/s00330-004-2593-9 1:STN:280:DC%2BD2M3itVWitw%3D%3D (Pubitemid 41166736)
24. Lowry R (2008) Clinical calculator 1: from an observed sample-estimates of population prevalence, sensitivity, specificity, predictive values, and likelihood ratios. VassarStats. http://faculty.vassar.edu/lowry/clin1.html. Accessed 17 February 2011
25. AM Chiarelli V Majpruz P Brown M Thériault R Shumak V Mai 2009 The contribution of clinical breast examination to the accuracy of breast screening J Natl Cancer Inst 101 1236 1243 19720967 10.1093/jnci/djp241
26. IM Obdeijn CE Loo AJ Rijnsburger MNJM Wasser E Bergers T Kok, et al. 2010 Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition Breast Cancer Res Treat 119 399 407 19876732 10.1007/s10549-009-0607-7
27. Lu W, de Bock GH, Schaapveld M, Baas PC, Wiggers T, Jansen L (2010) The value of routine physical examination in the follow up of women with a history of early breast cancer. Eur J Cancer (in press)
28. F Sendaǧ M Coşan Terek S Ozşener K Oztekin O Bilgin I Bilgen, et al. 2001 Mammographic density changes during different postmenopausal hormone replacement therapies Fertil Steril 76 445 450 11532462 10.1016/S0015-0282(01)01935-5